)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Theriva Biologics (TOVX) investor relations material
Theriva Biologics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary12 Nov, 2025
Executive summary
Focus shifted to oncology, with VCN-01 as lead candidate for pancreatic cancer and retinoblastoma, following the acquisition of VCN Biosciences.
Expanded clinical data for VCN-01 in metastatic PDAC from the VIRAGE Phase 2b trial presented at ESMO 2025, showing improved overall survival and progression-free survival with VCN-01 plus standard chemotherapy compared to chemotherapy alone.
Preclinical data for next-generation oncolytic virus VCN-12 presented at ESGCT, demonstrating enhanced cell killing and immune response in animal models.
Workforce reduced by 32% to prioritize business development, licensing, and pivotal trial preparation.
Cash position increased to $15.5M as of November 2025, expected to fund operations into Q1 2027 following recent capital raises.
Financial highlights
Net loss for Q3 2025 was $4.4M ($0.45/share), down from $7.7M ($6.81/share) in Q3 2024.
Net loss for the nine months ended September 30, 2025 was $21.7M ($3.38/share), compared to $21.2M ($24.47/share) in the prior year period.
General and administrative expenses for Q3 2025 decreased 18% year-over-year to $1.9M, mainly due to lower compensation costs.
R&D expenses for Q3 2025 decreased 7% year-over-year to $2.6M, reflecting lower clinical trial costs after completion of the VIRAGE Phase 2b trial.
Cash and cash equivalents were $7.5M at September 30, 2025, increasing to $15.5M in early November 2025 due to equity and warrant proceeds.
Outlook and guidance
Current cash expected to fund operations into Q1 2027, supporting regulatory, clinical, and preclinical activities, including close-out of VIRAGE trial and VCN-01 manufacturing scale-up.
Additional funding required for future Phase 3 trials and further development of SYN-004 and SYN-020; no committed sources of financing for these at present.
Strategic focus on advancing VCN-01, with out-licensing or partnering planned for SYN-004 and SYN-020.
Plans to discuss Phase 3 VCN-01 trial protocol with US and European regulators and design a Phase 2/3 trial in retinoblastoma for 2026.
General and administrative and R&D expenses anticipated to decrease further due to workforce reduction and completion of the VIRAGE trial.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Theriva Biologics earnings date
Q4 20256 Mar, 2026
Next Theriva Biologics earnings date
Q4 20256 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Theriva Biologics Inc. is a clinical-stage biotechnology company developing novel therapies for cancer and other serious diseases. The company focuses on oncolytic viruses and microbiome-based therapies designed to enhance the effectiveness of existing treatments and improve patient outcomes. Theriva’s pipeline includes investigational products targeting solid tumors, gastrointestinal diseases, and other conditions. The company is headquartered in Rockville, Maryland, and its shares are listed on the NYSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage